267 related articles for article (PubMed ID: 12673205)
1. Functional analysis of the N-terminal domain of the Myc oncoprotein.
Oster SK; Mao DY; Kennedy J; Penn LZ
Oncogene; 2003 Apr; 22(13):1998-2010. PubMed ID: 12673205
[TBL] [Abstract][Full Text] [Related]
2. New Myc-interacting proteins: a second Myc network emerges.
Sakamuro D; Prendergast GC
Oncogene; 1999 May; 18(19):2942-54. PubMed ID: 10378691
[TBL] [Abstract][Full Text] [Related]
3. The basic region/helix-loop-helix/leucine zipper domain of Myc proto-oncoproteins: function and regulation.
Lüscher B; Larsson LG
Oncogene; 1999 May; 18(19):2955-66. PubMed ID: 10378692
[TBL] [Abstract][Full Text] [Related]
4. Functional analysis of the carboxy-terminal transforming region of v-Myc: binding to Max is necessary, but not sufficient, for cellular transformation.
Min S; Mascarenhas NT; Taparowsky EJ
Oncogene; 1993 Oct; 8(10):2691-701. PubMed ID: 8378081
[TBL] [Abstract][Full Text] [Related]
5. Activation of gene transcription by the amino terminus of the N-Myc protein does not require association with the protein encoded by the retinoblastoma suppressor gene RB1.
Cziepluch C; Wenzel A; Schürmann J; Schwab M
Oncogene; 1993 Oct; 8(10):2833-8. PubMed ID: 8378092
[TBL] [Abstract][Full Text] [Related]
6. Mouse Sin3A interacts with and can functionally substitute for the amino-terminal repression of the Myc antagonist Mxi1.
Rao G; Alland L; Guida P; Schreiber-Agus N; Chen K; Chin L; Rochelle JM; Seldin MF; Skoultchi AI; DePinho RA
Oncogene; 1996 Mar; 12(5):1165-72. PubMed ID: 8649810
[TBL] [Abstract][Full Text] [Related]
7. Decreased tumorigenicity of c-Myc-transformed fibroblasts expressing active USF2.
Choe C; Chen N; Sawadogo M
Exp Cell Res; 2005 Jan; 302(1):1-10. PubMed ID: 15541720
[TBL] [Abstract][Full Text] [Related]
8. v-Myc, but not Max, possesses domains that function in both transcription activation and cellular transformation.
Min S; Taparowsky EJ
Oncogene; 1992 Aug; 7(8):1531-40. PubMed ID: 1630816
[TBL] [Abstract][Full Text] [Related]
9. YY1 can inhibit c-Myc function through a mechanism requiring DNA binding of YY1 but neither its transactivation domain nor direct interaction with c-Myc.
Austen M; Cerni C; Lüscher-Firzlaff JM; Lüscher B
Oncogene; 1998 Jul; 17(4):511-20. PubMed ID: 9696045
[TBL] [Abstract][Full Text] [Related]
10. Gene-target recognition among members of the myc superfamily and implications for oncogenesis.
O'Hagan RC; Schreiber-Agus N; Chen K; David G; Engelman JA; Schwab R; Alland L; Thomson C; Ronning DR; Sacchettini JC; Meltzer P; DePinho RA
Nat Genet; 2000 Feb; 24(2):113-9. PubMed ID: 10655054
[TBL] [Abstract][Full Text] [Related]
11. Repression of the human immunodeficiency virus type-1 long terminal repeat by the c-Myc oncoprotein.
Stojanova A; Caro C; Jarjour RJ; Oster SK; Penn LZ; Germinario RJ
J Cell Biochem; 2004 May; 92(2):400-13. PubMed ID: 15108364
[TBL] [Abstract][Full Text] [Related]
12. Involvement of the 'leucine zipper' region in the oligomerization and transforming activity of human c-myc protein.
Dang CV; McGuire M; Buckmire M; Lee WM
Nature; 1989 Feb; 337(6208):664-6. PubMed ID: 2645525
[TBL] [Abstract][Full Text] [Related]
13. Amino-terminal domains of c-myc and N-myc proteins mediate binding to the retinoblastoma gene product.
Rustgi AK; Dyson N; Bernards R
Nature; 1991 Aug; 352(6335):541-4. PubMed ID: 1865909
[TBL] [Abstract][Full Text] [Related]
14. c-Myc creates an activation loop by transcriptionally repressing its own functional inhibitor, hMad4, in young fibroblasts, a loop lost in replicatively senescent fibroblasts.
Marcotte R; Chen JM; Huard S; Wang E
J Cell Biochem; 2005 Dec; 96(5):1071-85. PubMed ID: 16167342
[TBL] [Abstract][Full Text] [Related]
15. Human c-Myc isoforms differentially regulate cell growth and apoptosis in Drosophila melanogaster.
Benassayag C; Montero L; Colombié N; Gallant P; Cribbs D; Morello D
Mol Cell Biol; 2005 Nov; 25(22):9897-909. PubMed ID: 16260605
[TBL] [Abstract][Full Text] [Related]
16. c-Myc initiates illegitimate replication of the ribonucleotide reductase R2 gene.
Kuschak TI; Kuschak BC; Taylor CL; Wright JA; Wiener F; Mai S
Oncogene; 2002 Jan; 21(6):909-20. PubMed ID: 11840336
[TBL] [Abstract][Full Text] [Related]
17. Omomyc, a potential Myc dominant negative, enhances Myc-induced apoptosis.
Soucek L; Jucker R; Panacchia L; Ricordy R; Tatò F; Nasi S
Cancer Res; 2002 Jun; 62(12):3507-10. PubMed ID: 12067996
[TBL] [Abstract][Full Text] [Related]
18. C-MYC: evidence for multiple regulatory functions.
Penn LJ; Laufer EM; Land H
Semin Cancer Biol; 1990 Feb; 1(1):69-80. PubMed ID: 2133113
[TBL] [Abstract][Full Text] [Related]
19. Low molecular weight inhibitors of Myc-Max interaction and function.
Yin X; Giap C; Lazo JS; Prochownik EV
Oncogene; 2003 Sep; 22(40):6151-9. PubMed ID: 13679853
[TBL] [Abstract][Full Text] [Related]
20. Role of myc amplification and overexpression in cell growth, differentiation and death.
Koskinen PJ; Alitalo K
Semin Cancer Biol; 1993 Feb; 4(1):3-12. PubMed ID: 8448376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
